½ÃÀ庸°í¼­
»óǰÄÚµå
1825367

´ÏÄÚÆ¾ ²­ ½ÃÀå : ¿¹Ãø(2025-2030³â)

Nicotine Gum Market - Forecasts from 2025 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Knowledge Sourcing Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 145 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

´ÏÄÚÆ¾ ²­ ½ÃÀåÀº CAGR 5.11%·Î, 2025³â 18¾ï 7,200¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 24¾ï 100¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

´ÏÄÚÆ¾ ²­Àº ´ã¹è ¼Òºñ¸¦ ÁÙÀÌ°í ±Ã±ØÀûÀ¸·Î ´ã¹è »ç¿ëÀ» Áß´ÜÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÈ ÀϹÝÀǾàǰ(OTC) ±Ý¿¬ º¸Á¶Á¦ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±¸°­ Á¡¸·¿¡¼­ Èí¼öµÇ´Â ´ÏÄÚÆ¾À» ¹æÃâÇÏ¿© Èí¿¬¿å±¸, ±Ý´ÜÁõ»ó, Èí¿¬ Ãæµ¿À» ¿ÏÈ­ÇÕ´Ï´Ù. 2mg, 4mg, 6mgÀÇ ¼¼ °¡Áö °­µµ°¡ ÀÖÀ¸¸ç, °³ÀÎÀÇ ÇÏ·ç ´ã¹è ¼Òºñ·®¿¡ ¸Â°Ô º¹¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼¼°è ´ÏÄÚÆ¾ ²­ ½ÃÀåÀº °Ç°­ ÀÎ½Ä Áõ°¡, Èí¿¬ °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¤ºÎ ¹× ºñÁ¤ºÎ±â±¸(NGO)ÀÇ Áö¿ø ³ë·Â¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ´ÏÄÚÆ¾ ²­ÀÇ ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀÌ ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå µ¿Çâ

´ÏÄÚÆ¾ ²­ ½ÃÀåÀº ¸î °¡Áö ÁÖ¿ä Æ®·»µå¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. Áß¿äÇÑ ¿øµ¿·ÂÀº Æó¾Ï, °ü»óµ¿¸Æ¼º ½ÉÀ庴, ±¸°­ÀεξÏ, ½Äµµ¾Ï, ³úÁ¹Áß, ·ù¸¶Æ¼½º °üÀý¿°, °áÇÙ, ¸é¿ª °ü·Ã Áúȯ µî Èí¿¬ °ü·Ã ÁúȯÀÇ ¹ß»ý·ü Áõ°¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ °Ç°­ À§Çè¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ´ÏÄÚÆ¾ ²­°ú °°Àº ±Ý¿¬ º¸Á¶Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸Å³â 5¿ù 31ÀÏ ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ '¼¼°è ±Ý¿¬ÀÇ ³¯'°ú °°Àº ¼¼°èÀûÀÎ ±Ý¿¬ Ä·ÆäÀΰú °øÁߺ¸°Ç ÀÌ´Ï¼ÅÆ¼ºê´Â ´ã¹èÀÇ ÆóÇØ¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ°í ±Ý¿¬ º¸Á¶Á¦ »ç¿ëÀ» Àå·ÁÇϰí ÀÖ½À´Ï´Ù. '´ã¹è ¾ø´Â ¾ÆÀ̵éÀ» À§ÇÑ Ä·ÆäÀÎ(Campaign for Tobaco-Free Kids)'°ú °°Àº NGO´Â ÀÌ·¯ÇÑ ³ë·ÂÀ» ´õ¿í ÁõÆø½ÃÄÑ Àü ¼¼°èÀûÀ¸·Î ´ã¹è »ç¿ë °¨¼Ò¸¦ ¿ËÈ£ÇÔÀ¸·Î½á ´ÏÄÚÆ¾ ²­¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¶Ç ´Ù¸¥ Ãß¼¼´Â ±Ý¿¬ Ä¡·áÀÇ Ã¤Åà Ȯ´ëÀÔ´Ï´Ù. ¼±Áø±¹°ú ½ÅÈï±¹ ½ÃÀå ¸ðµÎ Á¤ºÎ¿Í NGO°¡ ´ã¹è Áßµ¶ÀÚ, ƯÈ÷ ÀþÀº ÃþÀ» Áö¿øÇϱâ À§ÇØ ´ÏÄÚÆ¾ ²­À» Àû±ØÀûÀ¸·Î È«º¸Çϰí ÀÖ½À´Ï´Ù. ´ÏÄÚÆ¾ ĵµð, ºÎµå·¯¿î Áú°¨ÀÇ ²­ °³¹ß µî Á¦Ç° Çõ½Åµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü´Â ¿¬±¸°³¹ß(R&D)¿¡ ÅõÀÚÇÏ¿© È¿°úÀûÀÌ°í »ç¿ëÇϱ⠽¬¿î ±Ý¿¬º¸Á¶Á¦¸¦ ¿øÇÏ´Â ¼ÒºñÀÚÀÇ ±âÈ£¿¡ ¸ÂÃß¾î Á¦Ç° ¶óÀξ÷À» °­È­Çϰí ÀÖ½À´Ï´Ù. µµ½ÃÈ­¿Í °Ç°­ ÁöÇâ Áõ°¡´Â ÀÌ·¯ÇÑ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

¼ºÀå ÃËÁø¿äÀÎ

´ÏÄÚÆ¾ ²­ ½ÃÀåÀº °­·ÂÇÑ ±Ý¿¬ ÀÌ´Ï¼ÅÆ¼ºê¿Í ±Ý¿¬À» ½ÃµµÇÏ´Â °³ÀÎ Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±¹¹Î ÀÎ½Ä °³¼± Ä·ÆäÀΰú ¾ö°ÝÇÑ ±Ý¿¬ ±ÔÁ¦·Î ÀÎÇØ ±Ý¿¬ º¸Á¶Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, '¼¼°è ±Ý¿¬ÀÇ ³¯'À̳ª '´ã¹è ¾ø´Â ¾î¸°À̸¦ À§ÇÑ Ä·ÆäÀÎ'°ú °°Àº ¼¼°è ÀÌ´Ï¼ÅÆ¼ºê´Â Èí¿¬ÀÇ °Ç°­ À§Çè¿¡ ´ëÇØ ´ëÁßÀ» ±³À°Çϰí Èí¿¬ ¿å±¸¸¦ ¾ïÁ¦Çϱâ À§ÇØ ´ÏÄÚÆ¾ ²­À» »ç¿ëÇϵµ·Ï Àå·ÁÇÕ´Ï´Ù. °¢ Á¦Á¶¾÷üµéÀº ÁøÈ­ÇÏ´Â ¼ÒºñÀÚ ´ÏÁî¿¡ ´ëÀÀÇϱâ À§ÇØ Áú°¨À» °³¼±ÇÑ ¸¶½ºÅ©·ÎÄ¡, ²­ µî Çõ½ÅÀûÀÎ Á¦Ç°À» Ãâ½ÃÇϸç ÀÌ·¯ÇÑ ³ë·Â¿¡ ÈûÀ» º¸Å°í ÀÖ½À´Ï´Ù. Èí¿¬ °ü·Ã Áúº´, ƯÈ÷ Æó¾ÏÀÇ À¯º´·üÀÌ ³ô¾ÆÁö¸é¼­ ´ã¹è ÀÇÁ¸µµ¸¦ ³·Ãß´Â µµ±¸·Î¼­ ´ÏÄÚÆ¾ ²­¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

±×·¯³ª ½ÃÀåÀº ´ÏÄÚÆ¾ ²­°ú °ü·ÃµÈ ºÎÀÛ¿ëÀ¸·Î ÀÎÇÑ ÀáÀçÀû Á¦¾à¿¡ Á÷¸éÇϰí ÀÖÀ¸¸ç, ÀϺΠ¼ÒºñÀÚÃþ¿¡¼­ äÅÃÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »óȲ¿¡µµ ºÒ±¸Çϰí, °øÁߺ¸°Ç Ä·ÆäÀο¡ ÈûÀÔ¾î Àü ¼¼°èÀûÀ¸·Î ±Ý¿¬ ½Ãµµ Ƚ¼ö°¡ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Áö¸®Àû Àü¸Á

ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È ´ÏÄÚÆ¾ ²­ÀÇ ÁÖ¿ä ½ÃÀåÀ¸·Î ³²À» °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹Ì±¹ÀÌ ÀÌ Áö¿ªÀ» Áö¹èÇϰí ÀÖÀ¸¸ç, ÁÖ¿ä ºê·£µå´Â ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ Á¦Ç° Çõ½Å¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ´ÏÄÚ·¿(Nicorette)Àº ÃÖ±Ù ´õ ºÎµå·¯¿î Áú°¨ÀÇ ´ÏÄÚÆ¾ ²­°ú ¾ÆÀ̽º ¹ÎÆ® ¸¶¸§¸ð²ÃÀ» Ãâ½ÃÇÏ¿© »ç¿ëÀÚ °æÇèÀ» Çâ»ó½ÃŰ·Á´Â ¼ÒºñÀÚÀÇ ÃëÇâ¿¡ ºÎÀÀÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÅÈï±¹ ½ÃÀåÀÇ ¹ßÀüÀ¸·Î ºÏ¹Ì ½ÃÀå ¼ºÀå¼¼´Â À¯ÁöµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À¯·´µµ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ µîÀÇ ±¹°¡¿¡¼­ ÆÇ¸Å È£Á¶¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Áö¿ª Á¤ºÎ´Â ±Ý¿¬ Àü·«À» ¿ì¼±½ÃÇϰí ÀÖÀ¸¸ç, ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î´Â ÷´Ü ±Ý¿¬º¸Á¶Á¦Ç°¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ö¿ä Áõ°¡, ´ã¹è ±â¾÷°£ °æÀï ½ÉÈ­, »ç¾÷±âȸ È®´ë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÀϺ»ÀÌ ÀÌ Áö¿ªÀÇ ¼ºÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, Áß±¹°ú ÀεµÀÇ ¾ö°ÝÇÑ ±Ý¿¬¹ýÀÌ ±âÁ¸ ´ã¹è Á¦Ç°ÀÇ ´ëüǰÀ¸·Î ´ÏÄÚÆ¾ ²­¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

´ÏÄÚÆ¾ ²­ ½ÃÀåÀº °Ç°­ ÀÎ½Ä Áõ°¡, Èí¿¬ °ü·Ã Áúº´ Áõ°¡, °­·ÂÇÑ ±Ý¿¬ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÈûÀÔ¾î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºÏ¹Ì¿Í À¯·´Àº ¿©ÀüÈ÷ ÁÖ¿ä ½ÃÀåÀ̸ç, ¾Æ½Ã¾ÆÅÂÆò¾çÀº °­·ÂÇÑ ¼ºÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀ¸·Î ÀÎÇÑ µµÀü¿¡µµ ºÒ±¸Çϰí, Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß°ú Çõ½ÅÀûÀÎ Á¦Ç° Ãâ½Ã°¡ ½ÃÀåÀÇ ¸ð¸àÅÒÀ» À¯ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¾÷°è ÀÌÇØ°ü°èÀÚµéÀº ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ °øÁߺ¸°Ç Ä·ÆäÀÎÀ» Ȱ¿ëÇÏ°í ¼ÒºñÀÚ Ä£È­ÀûÀÎ Á¦Ç° °³¹ß¿¡ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù.

º» º¸°í¼­ÀÇ ÁÖ¿ä ÀåÁ¡

  • ÅëÂû·Â ÀÖ´Â ºÐ¼® : °í°´ ºÎ¹®, Á¤ºÎ Á¤Ã¥ ¹× »çȸ°æÁ¦Àû ¿äÀÎ, ¼ÒºñÀÚ ¼±È£µµ, »ê¾÷º°, ±âŸ ÇÏÀ§ ºÎ¹®¿¡ ÃÊÁ¡À» ¸ÂÃá ÁÖ¿ä Áö¿ª ¹× ½ÅÈï Áö¿ªÀ» Æ÷°ýÇÏ´Â »ó¼¼ÇÑ ½ÃÀå ºÐ¼®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.
  • °æÀï ±¸µµ: ¼¼°è ÁÖ¿ä ±â¾÷µéÀÌ Ã¤ÅÃÇϰí ÀÖ´Â Àü·«Àû Àü·«À» ÀÌÇØÇϰí, ÀûÀýÇÑ Àü·«À» ÅëÇÑ ½ÃÀå ħÅõ °¡´É¼ºÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ : ¿ªµ¿ÀûÀÎ ¿äÀΰú ¸Å¿ì Áß¿äÇÑ ½ÃÀå µ¿Çâ, ±×¸®°í À̵éÀÌ ÇâÈÄ ½ÃÀå ¹ßÀüÀ» ¾î¶»°Ô Çü¼ºÇÒ °ÍÀÎÁö¿¡ ´ëÇØ ¾Ë¾Æº¾´Ï´Ù.
  • ½ÇÇà °¡´ÉÇÑ Á¦¾È: ¿ªµ¿ÀûÀΠȯ°æ ¼Ó¿¡¼­ »õ·Î¿î ºñÁî´Ï½º ½ºÆ®¸²°ú ¼öÀÍÀ» ¹ß±¼Çϱâ À§ÇÑ Àü·«Àû ÀÇ»ç°áÁ¤¿¡ ÅëÂû·ÂÀ» Ȱ¿ëÇÕ´Ï´Ù.
  • ´Ù¾çÇÑ »ç¿ëÀÚ¿¡ ´ëÀÀ: ½ºÅ¸Æ®¾÷, ¿¬±¸±â°ü, ÄÁ¼³ÅÏÆ®, Áß¼Ò±â¾÷, ´ë±â¾÷¿¡ À¯ÀÍÇÏ°í ºñ¿ë È¿À²Àû ¿ä¼Ò.

¾î¶² ¿ëµµ·Î »ç¿ëµÇ´Â°¡?

»ê¾÷ ¹× ½ÃÀå ÀλçÀÌÆ®, »ç¾÷ ±âȸ Æò°¡, Á¦Ç° ¼ö¿ä ¿¹Ãø, ½ÃÀå ÁøÃâ Àü·«, Áö¸®Àû È®Àå, ¼³ºñ ÅõÀÚ °áÁ¤, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¹× ¿µÇâ, ½ÅÁ¦Ç° °³¹ß, °æÀïÀÇ ¿µÇâ

Á¶»ç ¹üÀ§

  • 2022-2024³â °ú°Å µ¥ÀÌÅÍ & 2025-2030³â ¿¹Ãø µ¥ÀÌÅÍ
  • ¼ºÀå ±âȸ, °úÁ¦, °ø±Þ¸Á Àü¸Á, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¹× µ¿Ç⠺м®
  • °æÀï»ç Æ÷Áö¼Å´×, Àü·« ¹× ½ÃÀå Á¡À¯À² ºÐ¼®
  • ¸ÅÃâ ¼ºÀå ¹× ¿¹Ãø ±¹°¡¸¦ Æ÷ÇÔÇÑ ºÎ¹® ¹× Áö¿ªº° ºÐ¼®
  • ±â¾÷ ÇÁ·ÎÆÄÀϸµ(ƯÈ÷ À繫 ¹× ÁÖ¿ä °³¹ß).

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå ÇöȲ

  • ½ÃÀå °³¿ä
  • ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ¹üÀ§
  • ½ÃÀå ¼¼ºÐÈ­

Á¦3Àå ºñÁî´Ï½º »óȲ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • PorterÀÇ Five Forces ºÐ¼®
  • ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
  • Á¤Ã¥ ¹× ±ÔÁ¦
  • Àü·«Àû Á¦¾È

Á¦4Àå ±â¼ú Àü¸Á

Á¦5Àå ´ÏÄÚÆ¾ ²­ ½ÃÀå : Åõ¿©·®º°

  • ¼­·Ð
  • 2mg
  • 4mg

Á¦6Àå ´ÏÄÚÆ¾ ²­ ½ÃÀå : À¯Åë ä³Îº°

  • ¼­·Ð
  • ¿Â¶óÀÎ
  • ¿ÀÇÁ¶óÀÎ
    • ½´ÆÛ¸¶ÄÏ ¹× ÇÏÀÌÆÛ¸¶ÄÏ
    • ÆíÀÇÁ¡
    • ¾à±¹

Á¦7Àå ´ÏÄÚÆ¾ ²­ ½ÃÀå : ¿¬·Éº°

  • ¼­·Ð
  • 18¼¼-30¼¼
  • 30¼¼-50¼¼
  • 50¼¼ ÀÌ»ó

Á¦8Àå ´ÏÄÚÆ¾ ²­ ½ÃÀå : Áö¿ªº°

  • ¼­·Ð
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • ³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ½ºÆäÀÎ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ±âŸ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • Àεµ³×½Ã¾Æ
    • ű¹
    • ±âŸ

Á¦9Àå °æÀï ȯ°æ°ú ºÐ¼®

  • ÁÖ¿ä ±â¾÷°ú Àü·« ºÐ¼®
  • ½ÃÀå Á¡À¯À² ºÐ¼®
  • ÇÕº´, Àμö, ÇÕÀÇ ¹× Çù¾÷
  • °æÀï ´ë½Ãº¸µå

Á¦10Àå ±â¾÷ °³¿ä

  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • ITC Limited
  • Cipla
  • Perrigo Company Plc
  • Fertin Pharma
  • Alchem International
  • Haleon Group
  • Dr. Reddy's Laboratories Ltd.
  • British American Tobacco plc

Á¦11Àå ºÎ·Ï

  • ÅëÈ­
  • ÀüÁ¦Á¶°Ç
  • ±âÁØ¿¬µµ¿Í ¿¹Ãø¿¬µµ ŸÀÓ¶óÀÎ
  • ÀÌÇØ°ü°èÀÚ¿¡°Ô À־ÀÇ ÁÖ¿ä ÀÌÁ¡
  • Á¶»ç ¹æ¹ý
  • ¾à¾î
LSH

The Nicotine Gum Market is expected to grow from USD 1.872 billion in 2025 to USD 2.401 billion in 2030, at a CAGR of 5.11%.

Nicotine gum serves as an over-the-counter (OTC) smoking cessation aid designed to assist individuals in reducing cigarette consumption and ultimately quitting tobacco use. By releasing nicotine absorbed through the oral mucosa, the gum helps alleviate cravings, withdrawal symptoms, and the urge to smoke. Available in 2 mg, 4 mg, and 6 mg strengths, the dosage is tailored to an individual's daily cigarette consumption. The global nicotine gum market is experiencing growth driven by rising health consciousness, increasing prevalence of smoking-related diseases, and supportive initiatives from governments and non-governmental organizations (NGOs). However, potential adverse effects of nicotine gum may pose challenges to market expansion.

Market Trends

The nicotine gum market is propelled by several key trends. A significant driver is the growing incidence of smoking-related illnesses, such as lung cancer, coronary heart disease, oropharyngeal and esophageal cancers, stroke, rheumatoid arthritis, tuberculosis, and immune-related disorders. Heightened awareness of these health risks has increased demand for smoking cessation aids like nicotine gum. Additionally, global anti-smoking campaigns and public health initiatives, such as the World Health Organization's "World No Tobacco Day" observed annually on May 31, promote awareness of tobacco's adverse effects and encourage the adoption of cessation products. NGOs like the Campaign for Tobacco-Free Kids further amplify these efforts, driving demand for nicotine gum by advocating for reduced tobacco use worldwide.

Another trend fueling market growth is the increasing adoption of smoking cessation therapies. Governments and NGOs in both developed and emerging markets are actively promoting nicotine gum to support tobacco-addicted individuals, particularly younger demographics. Product innovation, such as the development of nicotine lozenges and smoother-textured gums, also contributes to market expansion. Manufacturers are investing in research and development (R&D) to enhance product offerings, aligning with consumer preferences for effective and user-friendly cessation aids. Urbanization and rising health consciousness further bolster demand for these products.

Growth Drivers

The nicotine gum market is driven by robust anti-smoking initiatives and the growing number of individuals attempting to quit smoking. Public awareness campaigns and stringent anti-smoking regulations have heightened the demand for cessation aids. For example, global initiatives like World No Tobacco Day and the Campaign for Tobacco-Free Kids educate the public on smoking's health risks, encouraging the use of nicotine gum to manage cravings. Manufacturers support these efforts by introducing innovative products, such as lozenges and gums with improved textures, to meet evolving consumer needs. The rising prevalence of smoking-related diseases, particularly lung cancer, further drives demand for nicotine gum as a tool to reduce tobacco dependency.

However, the market faces potential constraints due to the adverse effects associated with nicotine gum, which may limit its adoption in some consumer segments. Despite this, the increasing number of quit attempts globally, supported by public health campaigns, continues to drive market growth.

Geographical Outlook

North America is projected to remain the leading market for nicotine gum throughout the forecast period, driven by a growing base of health-conscious consumers and supportive government initiatives. The United States dominates this region, with major brands focusing on product innovation to meet rising demand. For instance, Nicorette recently introduced a smoother-textured nicotine gum and an ice mint lozenge, catering to consumer preferences for enhanced user experience. These developments are expected to sustain market growth in North America.

Europe also holds a significant market share, with strong sales in countries such as Germany, the United Kingdom, France, and Italy. Regional governments are prioritizing smoking cessation strategies, further supporting market expansion. Meanwhile, the Asia Pacific region is anticipated to experience the highest compound annual growth rate (CAGR) over the forecast period. Factors driving this growth include increasing consumer demand for advanced cessation products, heightened competition among tobacco companies, and expanding commercial opportunities. Japan is expected to lead regional growth, while stringent anti-smoking laws in China and India are likely to boost demand for nicotine gum as an alternative to traditional tobacco products.

The nicotine gum market is poised for growth, driven by rising health awareness, increasing smoking-related illnesses, and robust anti-smoking initiatives. North America and Europe remain key markets, while Asia Pacific is expected to exhibit strong growth potential. Despite challenges from potential side effects, ongoing R&D and innovative product launches are likely to sustain market momentum. Industry stakeholders should focus on leveraging public health campaigns and developing consumer-friendly products to capitalize on these opportunities.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Nicotine Gum Market Segments:

By Dosage Type

  • 2 Mg
  • 4 Mg

By Distribution Channel

  • Online
  • Offline
  • Supermarket/Hypermarket
  • Convenience Stores
  • Pharmacies

By Age

  • 18 to 30 Years
  • 30 to 50 Years
  • Greater than 50 Years

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. NICOTINE GUM MARKET BY DOSAGE TYPE

  • 5.1. Introduction
  • 5.2. 2 Mg
  • 5.3. 4 Mg

6. NICOTINE GUM MARKET BY DISTRIBUTION CHANNEL

  • 6.1. Introduction
  • 6.2. Online
  • 6.3. Offline
    • 6.3.1. Supermarket/Hypermarket
    • 6.3.2. Convenience Stores
    • 6.3.3. Pharmacies

7. NICOTINE GUM MARKET BY AGE

  • 7.1. Introduction
  • 7.2. 18 to 30 Years
  • 7.3. 30 to 50 Years
  • 7.4. Greater than 50 Years

8. NICOTINE GUM MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. GlaxoSmithKline Plc
  • 10.2. Johnson and Johnson
  • 10.3. ITC Limited
  • 10.4. Cipla
  • 10.5. Perrigo Company Plc
  • 10.6. Fertin Pharma
  • 10.7. Alchem International
  • 10.8. Haleon Group
  • 10.9. Dr. Reddy's Laboratories Ltd.
  • 10.10. British American Tobacco plc

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key benefits for the stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦